All In Biotech

Drug Trial Radar · NCT07908329

Intradermal Influenza Vaccination

Characterization of Immune Response to Intradermal Influenza Vaccination

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 139 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

139

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

May 2029

Study completion May 2029

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chan Zuckerberg Initiative; Silicon Valley Community Foundation; Yale Development Award
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to characterize the immune response, both innate and adaptive, as well as locally and systemic, to intradermal (ID) vaccination. The intervention involves intradermal administration of an FDA-approved intramuscular seasonal influenza vaccine, using an FDA-approved device MicronJet. Investigators will measure antibody titers, cell subtypes, and multi-omic profiles, by collecting skin and peripheral blood at baseline and at several time points after vaccination. The primary objective is to identify baseline correlates of immune response in the skin and peripheral blood to the seasonal influenza vaccine. The investigators secondary goals are to describe the inflammatory response in the skin over time.

Conditions

  • Vaccine Reaction

Interventions

  • MicronJetDevice

    MicronJet 600 syringe will be used to administer intradermal flu vaccine injections

  • Fluzone® QuadrivalentBiological

    Intradermal injections of 0.3mL

  • Fluzone® QuadrivalentBiological

    Intramuscular injection of 0.3mL

  • Fluzone® High Dose QuadrivalentBiological

    For participants \>65 years old

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in antibody titer concentration to vaccination-BloodTime frame: Day 0 and Day 28
  2. Change in antibody titer concentration to vaccination-SkinTime frame: Day 0 and Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Church Street Research Unit

    New Haven, Connecticut · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.